SEMASIZE PLUS 2.4 is a once-weekly subcutaneous prescription injection containing semaglutide, which is primarily used for long-term chronic weight management, cardiovascular risk reduction, and the management of type 2 diabetes. It belongs to a class of medications called GLP-1 receptor agonists, which mimic natural metabolic hormones to regulate appetite, digestion, and blood sugar. The specific formulation of 9.6mg/3ml (3.2mg/ml) provides a multi-dose platform, typically delivering a maintenance dose of 2.4mg per week across four weekly doses.